By Admin 
- Sun Pharma’s fourth quarter profit increased by 26.2%.
Sun Pharma Deal: Sun Pharmaceutical Industries Ltd, the largest drug manufacturing company in India, will buy 100% stake in Innovcare Lifesciences Pvt Ltd for Rs 271.2 crore. The company gave this information in its exchange filing on Saturday.
What does Innovcare Lifesciences do?
Mumbai based Innovcare Lifesciences Private Limited mainly deals in marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. This company, started on July 21, 2024, is very popular in the category related to women’s health and wellness.
Innovcare’s revenue from operations for the business year 2025-26 was Rs 94.06 crore. Even in the previous financial year FY25, the company registered a revenue of Rs 86.09 crore. This shows that the company is continuously profitable.
Sun Pharmaceutical Industries has described this acquisition as a strategic investment to strengthen its product portfolio. This entire deal will be completed by July 31 through cash payment of Rs 271.2 crore. After the completion of the transaction, Innovcare Lifesciences will become a wholly owned government company of Sun Pharma.
Capture the nutraceutical market
Nutraceuticals (health supplements and lifestyle wellness) are growing rapidly in India, growing by 15% annually. In such a situation, by acquiring 100% stake in Innovcare Lifesciences, the company will strengthen its presence in this high-margin sector. This huge investment will boost Sun Pharma’s domestic formulation business, chronic and lifestyle therapy verticals.
fourth quarter results
In the fourth quarter of the business year 2026, the net profit of Sun Pharmaceutical Industries Limited has increased by 26.2% on an annual basis. During this period, the company earned a profit of Rs 2714 crore, which was Rs 2150 crore in the fourth quarter of last year.
In the fourth quarter, the company’s revenue jumped by 12.8% to Rs 14,612 crore, which was earlier Rs 12,959 crore. The company’s EBITDA increased by 6.2% year-on-year to Rs 3,954 crore, which is equal to the estimate of Rs 3946 crore. However, EBITDA margin declined to 27.1% from 28.7% in the fourth quarter of last year, but this was in line with the estimate of 27.2%.
Also read:
Warning: It is not wise to divide SIP of Rs 25000 into 10 places, this trick can backfire.